Important insomnia treatment Information


Subscribe


Orexigen Therapeutics reports net loss of $15.0M for three months ended December 31, 2009 (News-Medical-Net)

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the three months and year ended December 31, 2009.

Researchers turn to neurofeedback to clear the fog of chemo brain (The Cleveland Plain Dealer)

Fuzzy or foggy thinking. Inability to multitask. Difficulty concentrating. Memory problems. And, sometimes, insomnia and depression. In just the last decade chemotherapy patients got a name assigned to those side effects: Chemo brain.

Orexigen(R) Therapeutics Announces Fourth Quarter and Year Ended December 31, 2009 Financial Results (PR Newswire via Yahoo! Finance)

Orexigen® Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the three months and year ended December 31, 2009.

Pressure blamed for official suicide in SW China (People's Daily)

Work pressure was to be blamed for the suicide of a county official in southwest China's Yunnan Province, local authorities said on Monday. Li Jianrong, 36, was head of Lufeng County's water conservation bureau, when he jumped off from his sixth floor office at 6:25 p.m. on March 3. He died after first aid treatment. Li killed himself for being over-stressed with drought and quake relief work ...

Sleep, pray, love -- survey sheds light on U.S. bedtime routine (CNN)

Your racial and ethnic background can shape many aspects of your life: the type of food you eat, where you live, and your political views.

Hanoi archbishop hospitalised in Rome: report (AFP via Yahoo! News)

Hanoi's controversial Archbishop Joseph Ngo Quang Kiet has been admitted to hospital in Rome for "chronic insomnia and stress", the Asianews religious news agency said Monday.

Long-Term Efficacy Of Xenazine® (Tetrabenazine) For The Treatment Of Chorea Associated With Huntington's Disease (Medical News Today)

Lundbeck Inc. has announced the presentation of results from an open-label extension study of Xenazine® (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HD). Data from this study demonstrated that after an 80-week treatment period, subjects treated with Xenazine experienced a statistically significant reduction in chorea score (p These results are consistent with ...

03/08/2010 11:44 VIETNAM Archbishop of Hanoi in Rome for medical treatment (AsiaNews.it)

» by Emily Nguyễn Archbishop Kiet in Italy since March 5. Before leaving, he reassured those who fear an Vatican agreement with the Vietnamese Government which has repeatedly called for his removal from the capital.

Open-Label Continuation Study Supports Long-Term Efficacy of Xenazine® For Treatment Of Chorea Associated With ... (redOrbit)

Results achieved over 80 weeks of treatment consistent with statistically significant reduction in chorea demonstrated in pivotal studyLundbeck Inc.

Open-label continuation study supports long-term efficacy of Xenazine (tetrabenazine) for the treatment of chorea ... (EurekAlert!)

( Edelman Public Relations ) Lundbeck Inc. announced the presentation of results from an open-label extension study of Xenazine (tetrabenazine) for treatment of chorea associated with Huntington's disease. Data demonstrated that after an 80-week treatment period, subjects treated with Xenazine experienced a statistically significant reduction in chorea score (p